Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 16/20 | 0.66 |
| ▸ | EGFR | P00533 | 14/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128094 | 0.93 | FLT1 (0.63) | FLT1EGFRKDRNTRK1PRKCQ | |
| SCHEMBL7123612 | 0.87 | FLT1 (0.78) | FLT1EGFRKDR | |
| SCHEMBL7123570 | 0.85 | FLT1 (0.71) | FLT1EGFRKDR | |
| SCHEMBL7126436 | 0.85 | FLT1 (0.71) | FLT1EGFRKDR | |
| SCHEMBL7115578 | 0.84 | FLT1 (0.75) | FLT1EGFRKDR | |
| SCHEMBL7118674 | 0.84 | FLT1 (0.78) | FLT1EGFRKDR | |
| SCHEMBL7117833 | 0.82 | EGFR (0.76) | FLT1EGFRKDR | |
| SCHEMBL7115414 | 0.82 | FLT1 (0.69) | FLT1EGFRKDRNTRK1PRKCQ | |
| SCHEMBL7127001 | 0.82 | EGFR (0.77) | FLT1EGFRKDRPRKCQPRKCD | |
| SCHEMBL14777204 | 0.81 | NTRK1 (0.57) | FLT1EGFRKDRNTRK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | claimed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | FLT1 1043/4885EGFR 2961/4885KDR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.